Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tiragolumab
Biotech
Roche's TIGIT prospect fails another phase 3 lung cancer test
The phase 3 trial found adding TIGIT candidate tiragolumab to a checkpoint inhibitor had no effect on overall survival in non-small cell lung cancer.
Nick Paul Taylor
Nov 26, 2024 4:11am
Roche stops pivotal TIGIT trial as Keytruda lands knockout blow
Jul 4, 2024 5:10am
Gilead-Arcus' TIGIT gets high response in gastric cancer
Nov 7, 2023 9:40am
Roche posts TIGIT survival data after 'inadvertent disclosure'
Aug 23, 2023 5:36am
Roche scraps 5 trials while Alzheimer's, TIGIT plans still risky
Jul 21, 2022 10:39am
Roche combo shows 2 checkpoint inhibitors may be better than one
May 13, 2020 5:00pm
